Literature DB >> 17036616

Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel.

Troy D Chinevere1, Clinton K Murray, Earl Grant, Gregory A Johnson, Felix Duelm, Duane R Hospenthal.   

Abstract

The U.S. Army recently mandated that soldiers undergo glucose-6-phosphate dehydrogenase (G6PD) testing before deployment to malarious regions. We retrospectively characterize the presence and degree of G6PD deficiency in U.S. military personnel by sex, self-reported ethnicity, and World Health Organization deficiency classification through test results obtained October 1, 2004 through January 17, 2005. Data were available for 63,302 (54,874 males and 8,428 females) subjects; 2.5% of males and 1.6% of females were deficient, with most having only moderate enzyme deficiency. African American males (12.2%) and females (4.1%), along with Asian males (4.3%), had the highest rates of G6PD deficiency. Most males were found to have class III variants while most females were class IV variants. The most severely deficient were Asian males (class II). These results suggest that universal screening for G6PD deficiency is clinically warranted, and particularly essential for those male service members who self-report ethnicity as African American, Asian, or Hispanic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17036616     DOI: 10.7205/milmed.171.9.905

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  26 in total

Review 1.  Managing the jaundiced newborn: a persistent challenge.

Authors:  M Jeffrey Maisels
Journal:  CMAJ       Date:  2014-11-10       Impact factor: 8.262

2.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

3.  The African-American neonate at risk for extreme hyperbilirubinemia: a better management strategy is needed.

Authors:  W C Golden
Journal:  J Perinatol       Date:  2017-04       Impact factor: 2.521

4.  Frequency of glucose-6-phosphate dehydrogenase-deficient red blood cell units in a metropolitan transfusion service.

Authors:  Richard O Francis; Jeffrey Jhang; Jeanne E Hendrickson; James C Zimring; Eldad A Hod; Steven L Spitalnik
Journal:  Transfusion       Date:  2012-06-28       Impact factor: 3.157

5.  Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.

Authors:  J S Schildcrout; J C Denny; E Bowton; W Gregg; J M Pulley; M A Basford; J D Cowan; H Xu; A H Ramirez; D C Crawford; M D Ritchie; J F Peterson; D R Masys; R A Wilke; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-06-27       Impact factor: 6.875

6.  Molecular Characterization of G6PD Deficiency: Report of Three Novel G6PD Variants.

Authors:  Arun Kumar Arunachalam; S Sumithra; Madhavi Maddali; N A Fouzia; Aby Abraham; Biju George; Eunice S Edison
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-16       Impact factor: 0.900

7.  Acute hemolysis in a patient with a newly diagnosed glioblastoma.

Authors:  Adrian G Murphy; Stuart A Grossman
Journal:  CNS Oncol       Date:  2016-05-27

8.  Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans.

Authors:  Csaba P Kovesdy; Keith C Norris; L Ebony Boulware; Jun L Lu; Jennie Z Ma; Elani Streja; Miklos Z Molnar; Kamyar Kalantar-Zadeh
Journal:  Circulation       Date:  2015-09-18       Impact factor: 29.690

9.  Glucose-6-Phosphate Dehydrogenase Deficiency is Associated with Cardiovascular Disease in U.S. Military Centers.

Authors:  John E Thomas; Seungho Kang; Charles J Wyatt; Forest S Kim; A David Mangelsdorff; Fred K Weigel
Journal:  Tex Heart Inst J       Date:  2018-06-01

10.  Relating mutant genotype to phenotype via quantitative behavior of the NADPH redox cycle in human erythrocytes.

Authors:  Pedro M B M Coelho; Armindo Salvador; Michael A Savageau
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.